Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study

Purpose: Denosumab reduces bone resorption and improves bone mineral density (BMD). Studies have analyzed subsequent treatment transitioning from bisphosphonates to denosumab based on dual-energy X-ray absorptiometry scanning (DXA). Quantitative computed tomography (QCT) can help assess cortical and...

Full description

Bibliographic Details
Main Authors:	Koki Tsuchiya, Koji Ishikawa, Yoshifumi Kudo, Soji Tani, Takashi Nagai, Tomoaki Toyone, Katsunori Inagaki
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	Bone Reports
Subjects:	Osteoporosis Denosumab Bisphosphonates Quantitative computed tomography Subsequent treatment
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352187221003466

Similar Items

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
by: Yasuaki Hirooka, et al.
Published: (2021-09-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
by: Yilin Zhu, et al.
Published: (2020-05-01)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01)

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy
by: Dávid Száraz, et al.
Published: (2024-12-01)

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study
by: Alexander Stanoyevitch, et al.
Published: (2021-08-01)

Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis
by: Jia Yang, et al.
Published: (2024-09-01)

The effect of denosumab on pedicle screw fixation: a prospective 2-year longitudinal study using finite element analysis
by: Soji Tani, et al.
Published: (2021-03-01)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
by: Tetsuya Kaneko, et al.
Published: (2019-10-01)

Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab
by: Zhanna E. Belaya, et al.
Published: (2018-04-01)

Antiresorptive activity of denosumab in the treatment of osteoporosis in patients with rheumatoid arthritis
by: Nadezhda Y. Banshchikova, et al.
Published: (2018-12-01)

Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment
by: Chiao-Ling Chen, et al.
Published: (2024-12-01)

Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study
by: Tzai-Chiu Yu, et al.
Published: (2024-12-01)

Current treatment of osteoporosis
by: Subramanian Nallasivan
Published: (2019-01-01)

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)
by: Christian Meier, et al.
Published: (2017-08-01)

Periapical status in patients affected by osteoporosis: A retrospective clinical study
by: Erika Cadoni, et al.
Published: (2022-10-01)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
by: Arina Miyoshi, et al.
Published: (2021-07-01)

Osteoporosis in men: epidemiology and treatment with denosumab
by: Sidlauskas KM, et al.
Published: (2014-04-01)

Denosumab for the treatment of HIV-associated osteoporosis with fractures in a premenopausal woman
by: E. Marasco, et al.
Published: (2021-04-01)

Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01)

Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01)

Treatment of primary osteoporosis in men
by: Giusti A, et al.
Published: (2014-12-01)

Denosumab Treatment Improved Health‐Related Quality of Life in Osteoporosis: A Prospective Cohort Study
by: Shinya Hayashi, et al.
Published: (2019-07-01)

Denosumab for the treatment of osteoporosis
by: Michael R. McClung
Published: (2017-03-01)

Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case
by: Dahlia F Davidoff, et al.
Published: (2020-10-01)

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Lianghai Jiang, et al.
Published: (2022-11-01)

OSTEOPOROSIS AND JOINT REPLACEMENT
by: Holzer Gerold, et al.
Published: (2018-08-01)

Long-term consequences of osteoporosis therapy with denosumab
by: Francisco Bandeira, et al.
Published: (2022-12-01)

Denosumab treatment in patients with different courses of osteoporosis
by: Liudmila Ya. Rozhinskaya, et al.
Published: (2017-12-01)

Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy—A Registry‐Based Cohort Study
by: Judith Everts‐Graber, et al.
Published: (2022-10-01)

Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications
by: Kaleen N. Hayes, et al.
Published: (2024-03-01)

Denosumab Use in a Patient with Bisphosphonate-Resistant Humoral Hypercalcemia of Malignancy
by: Maali M. Milhem, et al.
Published: (2016-01-01)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
by: Ning Zhang, et al.
Published: (2020-05-01)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
by: Radosław Słopień, et al.
Published: (2017-10-01)

Cancer treatment-induced bone loss
by: Yong Jun Choi
Published: (2024-09-01)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
by: Jean-Jacques Body, et al.
Published: (2018-09-01)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
by: Ishikawa K, et al.
Published: (2016-12-01)

Treatment of patients with osteoporosis: issues of therapy duration, adherence, and replacement
by: N. V. Toroptsova
Published: (2018-12-01)

The efficacy of denosumab in Korean male patients with osteoporosis
by: Chaiho Jeong, et al.
Published: (2022-09-01)